Induced regulatory B cells stably expressing interleukin-10 reverse central nervous system autoimmunity by targeting myeloid cells.

Pharmacologically induced IL-10+ B cells effectively reverse CNS autoimmunity, with over 95% stability achieved using N6 compound in mice and humans.

• Why it matters: Understanding and harnessing IL-10-producing regulatory B cells is crucial for developing therapies for neuroinflammatory diseases like multiple sclerosis, where immune regulation is impaired.
• What they did: Researchers screened drugs and identified N6, which induces stable IL-10 expression in B cells; these cells accumulated in the CNS, differentiated into plasma cells, and modulated myeloid cell activity.
• The result: Transfer of IL-10+ B cells led to remission of experimental autoimmune encephalomyelitis, highlighting a promising pharmacological approach to treat neuroinflammation by targeting microglia.